Microcystin-based ADC Payload
Oncology (unspecified cancers)
Key Facts
About Simris Biologics
Simris Biologics is a Hamburg-based biotech subsidiary of the Simris Group, pioneering the use of cyanobacteria to develop novel payloads for Antibody-Drug Conjugates (ADCs). Its core asset is a proprietary platform that modifies cyanobacterial toxins to create highly potent, targeted cancer therapeutics with an improved safety profile, alongside a commercial business line of diagnostic standards. The company is pre-clinical, seeking early-stage licensing deals with biopharma partners to advance its pipeline, which is anchored by a lead microcystin variant candidate. Its strategy combines sustainable sourcing from the world's largest cyanobacterial strain library with a focus on unlocking the full therapeutic potential of ADCs.
View full company profileTherapeutic Areas
Other Oncology (unspecified cancers) Drugs
| Drug | Company | Phase |
|---|---|---|
| Pan-KRAS Inhibitor Programs | BlossomHill Therapeutics | Pre-clinical |
| pHLA-targeting Biotherapeutics | BioCopy | Discovery/Pre-clinical |
| In vivo CAR-T programs | Interius BioTherapeutics | Pre-clinical |